DDInter385 DDInter1658
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cisapride {u} (Compound) resembles {v} (Compound) Metoclopramide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Cisapride {u} (Compound) binds {v} (Gene) HTR2B
Cisapride {u} (Compound) upregulates {v} (Gene) PAK1
Cisapride {u} (Compound) downregulates {v} (Gene) PUF60
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Morphine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Cisapride (Compound) resembles Metoclopramide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Cisapride (Compound) binds HTR2B (Gene)
Cisapride (Compound) upregulates PAK1 (Gene)
Cisapride (Compound) downregulates PUF60 (Gene)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Haloperidol